1. Generics Bulletin
  2. >>Products
  3. >>Biosimilars

Biogen’s RoActemra Biosimilar Begins EU Approvals Process

The BIIB800 Candidate Is Only the Latest Of Biogen’s Deal-Driven Biosimilars

 
• By Rosalind Rei

The European Medicines Agency has accepted Biogen’s marketing authorization submission for its BIIB800, developed by Chinese firm Bio-Thera.

Vial labelled tocilizumab
• Source: Shutterstock

The European Medicines Agency has accepted Biogen’s tocilizumab biosimiliar which references Genentech’s RoActemra. It is an anti-interleukin-6 receptor monoclonal antibody which is indicated in Europe as an intravenous formulation for severe, active, and progressive rheumatoid arthritis in adults.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Products

J&J Denied Injunction Over Private-Label Ustekinumab In US

 
• By Dave Wallace

Stelara originator J&J has been denied in its initial attempt to prevent Samsung Bioepis and ustekinumab biosimilar partner Sandoz from selling a private-label version of the product through a PBM in the US.

UK Forxiga SPCs Wiped Out As Trio Succeed With Plausibility Attack

 
• By Dean Rudge

Generic competition to AstraZeneca’s blockbuster SGLT2 inhibitor Forxiga (dapagliflozin) treatment for diabetes may hit England and Wales earlier than 2028 after a pair of SPCs were invalidated following proceedings initiated by a trio of generics manufacturers.

What’s Next? Five Things To Look Out For In May

 
• By Dean Rudge

Generics Bulletin previews the most noteworthy and anticipated events for May 2025.